INT157765

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 2002
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 32
Total Number 34
Disease Relevance 35.72
Pain Relevance 1.15

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

endosome (CDH1) cell adhesion (CDH1) Golgi apparatus (CDH1)
plasma membrane (CDH1) cytoplasm (CDH1)
Anatomy Link Frequency
plasma 2
skin 2
neck 1
embryos 1
melanocytes 1
CDH1 (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 19 99.90 Very High Very High Very High
cINOD 11 95.64 Very High Very High Very High
fibrosis 66 94.72 High High
metalloproteinase 63 73.12 Quite High
Inflammation 77 67.84 Quite High
palliative 17 67.84 Quite High
Nerve growth factor 4 67.52 Quite High
tolerance 2 53.80 Quite High
antagonist 38 43.96 Quite Low
COX-2 inhibitor 2 42.12 Quite Low
Disease Link Frequency Relevance Heat
Adhesions 137 100.00 Very High Very High Very High
Metastasis 451 99.96 Very High Very High Very High
Carcinoma 344 99.80 Very High Very High Very High
Lobular Carcinoma 20 99.80 Very High Very High Very High
Cancer 2235 99.74 Very High Very High Very High
Malignant Neoplastic Disease 99 99.72 Very High Very High Very High
Skin Cancer 405 99.48 Very High Very High Very High
Breast Cancer 69 99.48 Very High Very High Very High
Squamous Cell Carcinoma 11 99.28 Very High Very High Very High
Repression 26 99.20 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The observed decrease in CDH1 (E-cadherin) in CC (p-value = 0.0045) also matched previously published reports, as did the decrease in VIM (vimentin) expression in Chr RCCa [13,16].
Negative_regulation (decrease) of E-cadherin associated with renal cancer and carcinoma
1) Confidence 0.53 Published 2002 Journal BMC Bioinformatics Section Body Doc Link PMC130042 Disease Relevance 1.34 Pain Relevance 0
The observed decrease in CDH1 (E-cadherin) in CC (p-value = 0.0045) also matched previously published reports, as did the decrease in VIM (vimentin) expression in Chr RCCa [13,16].
Negative_regulation (decrease) of CDH1 associated with renal cancer and carcinoma
2) Confidence 0.53 Published 2002 Journal BMC Bioinformatics Section Body Doc Link PMC130042 Disease Relevance 1.33 Pain Relevance 0
Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa.
Negative_regulation (suppresses) of CDH1 associated with aspirin
3) Confidence 0.43 Published 2010 Journal Dig. Dis. Sci. Section Title Doc Link 19184424 Disease Relevance 0.85 Pain Relevance 0.48
The inactivation of E-cadherin gene by methylation seems to play a role during progression of endometrioid carcinoma, since it is most frequently found in grade 3 and least frequently in grade 1 tumors [10].
Negative_regulation (inactivation) of E-cadherin gene associated with endometroid carcinoma and cancer
4) Confidence 0.38 Published 2010 Journal Obstetrics and Gynecology International Section Body Doc Link PMC2846683 Disease Relevance 1.61 Pain Relevance 0
Among them, an essential role for Snail1 has been highlighted by the general induction of the expression of this gene during EMT in many cell lines and especially by the lack of E-cadherin down-regulation during gastrulation of Snail1 deficient murine embryos [3].
Negative_regulation (regulation) of E-cadherin in embryos
5) Confidence 0.32 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2680015 Disease Relevance 0.77 Pain Relevance 0.03
Also, it is becoming increasingly accepted that tumor cells may not necessarily undergo a complete transition, but rather seem to adopt different "quasi-mesenchymal" states which, in addition to the transient nature of EMT and the contribution of other E-cadherin repressors, may explain the lack of correlation between SNAI1 expression and the mesenchymal phenotype, including E-cadherin loss.
Negative_regulation (loss) of E-cadherin associated with cancer
6) Confidence 0.20 Published 2010 Journal BMC Clin Pathol Section Body Doc Link PMC2829523 Disease Relevance 0.57 Pain Relevance 0
A similar situation was found for E-cadherin with areas of distinct membrane staining and areas of E-cadherin loss occasionally present in the same tumor.
Negative_regulation (loss) of E-cadherin associated with cancer
7) Confidence 0.20 Published 2010 Journal BMC Clin Pathol Section Body Doc Link PMC2829523 Disease Relevance 1.11 Pain Relevance 0
E-cadherin loss was not associated with shorter EFS and OS in our cohort.
Negative_regulation (loss) of E-cadherin
8) Confidence 0.20 Published 2010 Journal BMC Clin Pathol Section Body Doc Link PMC2829523 Disease Relevance 0.95 Pain Relevance 0
EMT can be induced by a variety of molecules characterized by one common activity which is the down-regulation of E-cadherin by transcriptional repression.
Negative_regulation (regulation) of E-cadherin associated with repression
9) Confidence 0.15 Published 2010 Journal BMC Clin Pathol Section Body Doc Link PMC2829523 Disease Relevance 0.59 Pain Relevance 0
As in several previous studies (Additional file 6), SNAI1 expression in our cohort was not significantly associated with E-cadherin loss.
Negative_regulation (loss) of E-cadherin
10) Confidence 0.15 Published 2010 Journal BMC Clin Pathol Section Body Doc Link PMC2829523 Disease Relevance 0.57 Pain Relevance 0
However, no significant difference was found between tumor and metastasis indicating that FAK gain and E-cadherin loss might be early events during tumor development.
Negative_regulation (loss) of E-cadherin associated with cancer and metastasis
11) Confidence 0.15 Published 2010 Journal BMC Clin Pathol Section Body Doc Link PMC2829523 Disease Relevance 1.57 Pain Relevance 0
A mesenchymal-like immunoprofile in primary tumors characterized by E-cadherin loss (n = 29, 63%) or high cytoplasmic FAK expression (n = 10, 22%) was associated with N(+) status and tumor recurrence/new primary, respectively.


Negative_regulation (loss) of E-cadherin associated with cancer and recurrence
12) Confidence 0.13 Published 2010 Journal BMC Clin Pathol Section Abstract Doc Link PMC2829523 Disease Relevance 1.56 Pain Relevance 0
However, significant nuclear SNAI1 expression was present, focal areas of E-cadherin loss could be discerned and p63 was absent.


Negative_regulation (loss) of E-cadherin
13) Confidence 0.13 Published 2010 Journal BMC Clin Pathol Section Body Doc Link PMC2829523 Disease Relevance 1.06 Pain Relevance 0.10
The epithelial environment the cutaneous melanocytes reside in leads to the cells having more epithelial qualities of which downregulation of the molecule E-cadherin during local invasion is an example.
Negative_regulation (downregulation) of E-cadherin in melanocytes
14) Confidence 0.11 Published 2010 Journal Dermatology Research and Practice Section Body Doc Link PMC2902045 Disease Relevance 0.94 Pain Relevance 0
Briefly these changes include environment independent growth; insensitivity to antigrowth factors (loss of tumor suppressor genes); evasion of apoptosis (producing survival factors); limitless replicative potential (turning on telomerase); sustained angiogenesis (producing VEGF inducer) and tissue invasion and metastasis (inactivation of E-cadherin).
Negative_regulation (inactivation) of E-cadherin associated with cancer, apoptosis and metastasis
15) Confidence 0.11 Published 2007 Journal Cancer Informatics Section Body Doc Link PMC2675843 Disease Relevance 1.50 Pain Relevance 0
was shown to upregulate Snail and to downregulate E-cadherin in head and neck squamous carcinoma cells [49], our initial analysis revealed no major changes in the expression of epithelial or mesenchymal markers in colon cancer cells exposed to macrophage-derived factors.
Negative_regulation (downregulate) of E-cadherin in neck associated with squamous cell carcinoma and colon cancer
16) Confidence 0.07 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2908545 Disease Relevance 1.42 Pain Relevance 0.03
The EMT program involves the downregulation of epithelial proteins such as E-cadherin and cytokeratins, and the upregulation of mesenchymal proteins including Fibronectin, N-cadherin, and Vimentin.
Negative_regulation (downregulation) of E-cadherin
17) Confidence 0.07 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2840411 Disease Relevance 0.77 Pain Relevance 0.03
Significant ET-1-induced mRNA expression of the transcription factor Snail, which has been identified a potent inhibitor of E-cadherin expression in melanoma, closely correlates with downregulation of E-cadherin.
Negative_regulation (downregulation) of E-cadherin associated with skin cancer
18) Confidence 0.07 Published 2004 Journal J Transl Med Section Body Doc Link PMC436068 Disease Relevance 0.86 Pain Relevance 0.14
Some similarities can be drawn with breast cancer: diffuse-type gastric cancers and lobular invasive breast carcinomas are both associated with E-cadherin loss, which is inversely correlated with HER2 amplification/overexpression which is more common in ductal invasive breast carcinomas and intestinal-type gastric cancers.
Negative_regulation (loss) of E-cadherin associated with breast cancer and stomach cancer
19) Confidence 0.07 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.49 Pain Relevance 0
Aberrant methylation can begin very early in tumor progression by causing loss of cell cycle control (p16) [83], loss of mismatch repair function (MLH1) [84] and loss of cell-cell interaction (E-cadherin).
Negative_regulation (loss) of E-cadherin in MLH1 associated with cancer
20) Confidence 0.07 Published 2003 Journal Respir Res Section Body Doc Link PMC314397 Disease Relevance 0.73 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox